文献速递妇科肿瘤

BRCA1/2致病性变异携带者与子宫内膜癌风险:一项队列研究

BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
PubMed 文献 · Eur J Cancer · 2020-07-19

该研究基于英国2609例BRCA致病性变异携带者(1350例BRCA1、1259例BRCA2)的队列数据,计算子宫内膜癌的标准化发病比(SIR),并对15例浆液性子宫内膜癌进行体细胞BRCA测序。未发现总体或浆液样子宫内膜癌风险显著升高(SIR=1.70,95%CI 0.74-3.33),且未检出BRCA致病性变异;结果不受BRCA基因型、既往乳腺癌或他莫昔芬暴露影响。

要点

  • BRCA1/2致病性变异携带者总体及浆液样子宫内膜癌风险未显著升高。
  • SIR=1.70(95%CI 0.74-3.33),受BRCA基因型、乳腺癌史或他莫昔芬影响不大。
  • 仅以预防为目的的子宫切除术可能获益有限。

核心结论

  • BRCA致病性变异携带者与一般人群相比,全部类型或浆液样子宫内膜癌风险未见显著增加。
  • 数据提示若仅作为预防措施,子宫切除术可能不会带来显著获益。

研究设计与样本

  • 基于英国BRCA致病性变异携带者队列,共纳入2609例女性(1350例BRCA1、1259例BRCA2)。
  • 计算四个不同队列的标准化发病比(SIR),参照国家子宫内膜癌发病率。
  • 对15例浆液性子宫内膜癌进行体细胞BRCA测序以检测致病性变异。

主要发现

  • 所有 examined 队列中,总体或浆液样子宫内膜癌风险均无显著增加(SIR=1.70,95%CI 0.74-3.33)。
  • 未诊断任何浆液性子宫内膜癌病例。
  • 结果不受受累BRCA基因、既往乳腺癌或他莫昔芬使用影响。
  • 所检测的浆液性子宫内膜癌中均未检出BRCA致病性变异。

关键数值与推荐

  • SIR=1.70(95%CI 0.74-3.33)用于评估总体子宫内膜癌风险,未达统计学显著。
  • 浆液样子宫内膜癌队列中无病例诊断。
  • 15例浆液性子宫内膜癌体细胞测序均未发现BRCA致病性变异。

临床怎么用

  • 对于BRCA致病性变异携带者,常规子宫内膜癌风险评估可不因BRCA状态而显著上调。
  • 在风险降低性双侧输卵管卵巢切除术中,预防性子宫切除术的额外获益证据有限。

局限性

  • 前瞻性诊断的子宫内膜癌病例数较少(仅2例)。
  • 浆液性子宫内膜癌的体细胞BRCA测序样本量小(15例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An association between BRCA pathogenic variants and an increased endometrial cancer risk, specifically serous-like endometrial cancer, has been postulated but remains unproven, particularly for BRCA2 carriers. Mechanistic evidence is lacking, and any link may be related to tamoxifen exposure or testing bias. Hysterectomy during risk-reducing bilateral salpingo-oophorectomy is, therefore, of uncertain benefit. Data from a large, prospective cohort will be informative. METHODS: Data on UK BRCA pathogenic variant carriers were interrogated for endometrial cancer diagnoses. Standardised incidence ratios (SIRs) were calculated in four distinct cohorts using national endometrial cancer rates; either from 1/1/1980 or age 20, prospectively from date of personal pathogenic variant report, date of family pathogenic variant report or date of risk-reducing salpingo-oophorectomy. Somatic BRCA sequencing of 15 serous endometrial cancers was performed to detect pathogenic variants. RESULTS: Fourteen cases of endometrial cancer were identified in 2609 women (1350 BRCA1 and 1259 BRCA2), of which two were prospectively diagnosed. No significant increase in either overall or serous-like endometrial cancer risk was identified in any of the cohorts examined (SIR = 1.70, 95% confidence interval = 0.74-3.33; no cases of serous endometrial cancer diagnosed). Results were unaffected by the BRCA gene affected, previous breast cancer or tamoxifen use. No BRCA pathogenic variants were detected in any of the serous endometrial cancers tested. CONCLUSIONS: Women with a BRCA pathogenic variant do not appear to have a significant increased risk of all-type or serous-like endometrial cancer compared with the general population. These data provide some reassurance that hysterectomy is unlikely to be of significant benefit if performed solely as a preventive measure.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kitson SJ, Bafligil C, Ryan NAJ, et al. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study. Eur J Cancer. 2020. PMID: 32698099. doi:10.1016/j.ejca.2020.05.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。